Tag Archive: horizon2020

  1. EAVI2020 continues the fight | World AIDS Day 2021

    Leave a Comment

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

    Click on each image to find out about EAVI2020’s clinical trials.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

  2. World AIDS DAY Part 1: EAVI2020’s research to a better future | Trial EAVI2020_3Sm

    Leave a Comment

    Hi! I’m the EAVI2020-3Sm trial and I am testing the VAC02 vaccine. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly Neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. The first in man clinical trial will discern the safety and the immunogenicity of VAC02 as well as the induction of broadly neutralizing antibodies against HIV-1.

    Let me introduce you the team: Robin Shattock (Imperial College London, Study sponsor, UK), Behazine Combadiere, Vincent Vieillard and Patrice Debre (Institut National de Santé et de Recherche Medicale – Inserm, Cimi-Paris, France), Agence Nationale de Recherche sur le SIDA et Maladies Infectieuses Emergentes (ANRS-MIE, France) and Minka Therapeutics (France), they all work together to ensure I am successful!

    Progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Peptide-based vaccination has become one of the challenges of this decade. Based on the discovery of natural broadly neutralizing antibodies against a conserved short epitope of GP41 in long-term non progressor HIV+ patients however rarely observed in HIV progressors, the EAVI2020-3Sm trial will be pioneering in the induction of such antibodies against HIV in man using VAC02 designed vaccine. Furthermore, the translation of VAC02 vaccine candidate into an experimental medicine (EM) study with results expected in 2022 will accelerate progress in the development of an HIV-1 vaccine.

    Find out more about the other EAVI2020 trials taking place:

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2022, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  3. World AIDS DAY Part 4: EAVI2020’s research to a better future | Trial HIV-CORE 0051

    Leave a Comment

    Hi! I am Trial HIV-CORE 0051. I am a phase 1/2a open-label trial to assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.HTI and MVA.HTI given sequentially to healthy HIV-1/2 negative adult volunteers at the Jenner Institute, University of Oxford. Our trial aims to establish the initial safety and immunogenicity of the candidate on the path towards a preventive use of this strategy and is complemented by a series of HIV cure trials in early-treated PLWH.

    The HIV-CORE 0051 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non-Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze along with the many other team members that make up the HIV-CORE 0051 Trial team, in close collaboration with AELIX.

    The trial evaluates a candidate T-cell vaccine, which are being developed by a biotech company, AELIX Therapeutics. The regimen utilizes a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with a replication-deficient poxvirus vector called MVA. Both vectors deliver protein HTI (HIVACAT T-cell Immunogen) designed to generate protective HIV-1-specific T-cell targeting vulnerable sites of HIV-1. The HTI design was informed by human data, whereby the HTI-specific T cells were associated with better viral control in more than 1,000 people living with HIV-1 (PLWH) within a broad HLA class I and class II allele coverage. The immunogen was designed by the team led by Professor Christian Brander and Dr Beatriz Mothe at the Institut de Recerca de la Sida – IrsiCaixa in Barcelona.

    For the last decade, the HIV vaccine development has been almost entirely preoccupied with antibody-based protection, while the T-cell vaccines have been sadly ignored. It is only recently that highly rational T-cell strategies are being resurrected mainly in the context of HIV cure, where effective killer T cells will likely be key for drug-free HIV remission, perhaps even eradication. Current prevention focuses on behavioural and biomedical interventions and provision of antiretroviral drugs, however, an effective HIV-1 vaccine will help many people beyond the reach of today’s treatment and prevention options. Our trial which is aiming to understand the mechanisms and paths towards induction of protective T cells is therefore highly topical.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  4. World AIDS DAY Part 5: EAVI2020’s research to a better future | Trial BCN03

    Leave a Comment

    Hi, I am EAVI2020 trial BCN03. Our trial takes place at IRSICAIXA with Christian Brander (Principal Investigator, IRSICAIXA) Beatriz Mothe (Principal Investigator, IRSICAIXA), working in collaboration with Rogier Sanders (Principal Investigator, AMC) and Dietmar Katinger (Principal Investigator, POLYMUN). Our trial focuses on a combined T- and B-cell, therapeutic HIV vaccine combining the HTI T cell vaccines with SOSIP envelope immunogens.

    Our trial is primarily focusing on the safety of the intervention and whether the intervention can induce sustained virus control once antiretroviral therapy (ART) is stopped. What sets our trial apart is that this is the first therapeutic vaccine trial that combines potent T and B cell immunogens in a combination regimen. We are hoping that this trial will test whether the addition of a B cell immunogen component to a T cell vaccine regimen can improve post-vaccination virus control compared to a single component regimen.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  5. World AIDS DAY Part 2: EAVI2020’s research to a better future | Trial HIV-CORE 0052

    Leave a Comment

    Hi! I am Trial HIV-CORE 0052; a phase I open-label trial aiming to establish and assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3+MVA.tHIVconsv4 given in combination to healthy volunteers at low risk for HIV-1 infection at The Jenner Institute, University of Oxford London (Trial Sponsor) which will be followed by further studies towards both prevention of HIV infection and an HIV cure.

    The HIV-CORE 0052 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze are aiming to test a candidate T-cell vaccine strategy against HIV-1. The tested regimen consists of a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with two replication-deficient poxviruses called MVA. These vectors deliver three unique mosaic algorithm-computed immunogens derived from the six most functionally conserved regions of the HIV proteome, collectively called HIVconsvX. Two regions are from the Gag including the whole capsid protein p24 and four are from the Pol proteins. These regions are common to most global HIV-1 variants and are hard to change and escape. These vaccines are so-called subunit genetic vaccines, are designated ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4 and aim to induce protective killer T-cell responses targeting HIV-1 ‘where it hurts’. If effective, they could work across all major HIV-1 clades and be deployed in all geographical regions.

    Throughout the challenging years of HIV vaccine development, when for the last decade most of the field has almost entirely focused on B-cell biology and antibody-based protection, Professor Hanke remained standing as one of a very few T-cell vaccinologists believing in vaccine-inducible protective cellular immunity, improving, and testing his highly rational T-cell strategy, which is now very much at the forefront of the current efforts.

    An HIV vaccine is urgently needed, however, simple vaccine solutions for this most difficult of viruses have remained extremely elusive. Development of an effective vaccine has been a slow and difficult process over four decades, but remarkable progress has been made in recent years. The experience with COVID-19 vaccines underscores how technologies under development for decades, such as RNA vaccines from 2001 and adenoviral vectors since 1991, can suddenly emerge as a leading and highly effective approach by building on decades of effort. Prof Hanke thinks it is likely that T cell-inducing vaccines for HIV-1 will reach this tipping point in the next 5 years and emerge as an additional tool to help control the HIV pandemic.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  6. World AIDS DAY Part 3: EAVI2020’s research to a better future | Trial EAVI2020_01

    Leave a Comment

    Hi! I am trial EAVI2020_01. Here at Imperial College London, both scientists and clinicians are leading my study which is modelling the interaction between rationally designed synthetic model viral protein immunogens (EAVI2020_01). We are studying immune responses to several different proteins that are modelled on HIV. The immunogens have a protein-adjuvant design and are given as an injection into the arm.

    Despite global efforts, HIV has proven one of the most difficult infections against which to develop a vaccine. We use sophisticated proteins that have been precisely developed to overcome these natural barriers. If the responses are promising, then we will have an early blueprint for making an HIV vaccine. Working on this trial are Professor Robin Shattock (Imperial College London, Scientific Lead), Dr Katrina Pollock (Imperial College London, Chief Investigator), and Dr Hannah Cheeseman (Imperial College London, Laboratory Lead).

    Vaccines are typically developed by focussing on the infection and not the immune response. The effectiveness of these vaccines is dependent on how most of us would usually respond to the infection if we were to come into contact with it. This strategy for making vaccines is restricting. For example, almost everyone who gets exposed to HIV will develop life threatening diseases without treatment.  The usual immune response is not protective.  The EAVI2020_01 study takes a different approach. Proteins that mimic the hidden parts of HIV are given several times to shepherd the body’s response precisely to make antibodies. The aim is that these antibodies will be broadly protective against all strains of HIV.

    The goal of HIV vaccine research is to make vaccines that induce broadly protective antibodies. This study will tell us how close we are to being able to do that. A successful outcome would pioneer the design of new vaccines for HIV and other highly challenging infectious diseases.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  7. EAVI2020 quarterly newsletter | April 2021

    Leave a Comment

    Download the April 2021 newsletter (.pdf)

     

    In this issue:

    • EAVI2020 receives extension and clinical trials resume
    • EAVI2020 consortium at HIVR4P
    • Students in Focus: Narcís Saubi, Vall d’Hebron Research Institute (VHIR)
    • Publications with EAVI2020
    • EAVI2020 out and about: International Women’s Day
    • HIV/AIDS news: COVID-19 disruptions to HIV prevention could increase new infections amongst men
    • Other news: EAVI2020 lead investigator, Prof Robin Shattock profiled in The Lancet

     

    Foreword from Robin 

    Following a challenging year in the face of the COVID-19 pandemic the consortium is excited to be progressing again at full speed.

    We were delighted to receive a no cost extension from the EU that will allow us to complete our full programme of research and make up for delays caused by multiple lockdowns across the EU. We continue to invest in the training and mentorship of gifted young researchers to ensure a rich talent pool for the future, some of whom are highlighted in this newsletter. In our final year we are conducting seven clinical trials to evaluate ten new vaccine candidates, demonstrating an unprecedented level of translation from discovery to clinical evaluation. Our clinical trials are underpinned by an integrated approach designed to maximise our understanding of human immunity to vaccination and the pathways for driving B and T cell breadth to combat the extraordinary diversity of circulating HIV strains. These studies will be the culmination of our discovery program, will significantly expand scientific understanding and provide a pipeline of products with potential for moving into later stage product development. The entire EAVI2020 team are galvanised around maximising the potential of our discovery program and building a sustainable legacy for HIV vaccine research in the EU.

    Professor Robin Shattock
    EAVI2020 coordinator and on behalf of the EAVI2020 consortium

    Read the rest of the newsletter here

  8. EAVI2020 extended and trials resume

    Leave a Comment

    As new light springs at the horizon with the rollout of efficacious COVID-19 vaccines, EAVI2020 has received a 12-month extension and its clinical studies across Europe are resuming.

    A new year, and a very different landscape from the last. EAVI2020 clinical work is coming out of its semi-hibernating state and the prospects seem brighter for 2021. Just this past month, EAVI2020’s funding body, the European Commission has given EAVI2020 an extra 12 months of breathing space. This is on top of an already granted 6-month extension which means EAVI2020 now has an expected closure date in April 2022. This speaks volumes as to how the COVID-19 pandemic has hindered EAVI2020 research. Nonetheless, the European Commission’s commitment to developing effective vaccine candidates for HIV remains undeterred, with continuing support for EAVI2020’s contribution.

    EAVI2020 has already achieved many of its initial objectives from 2015 but there is so much still to do. With study resumption getting underway, the EAVI2020 consortium is eager to dive back in.

    At Imperial College London, UK, the screening of new potential volunteers is resuming in the series of clinical experimental medicine studies (read more about the mosaic trial). The study is assessing how different protein immunogen combinations influence the development of protective antibodies against HIV, with the goal of inducing broadly neutralising antibodies. The first immunogen dose was administered on March 28 2019 at NIHR Imperial CRF, Hammersmith Hospital, London, and almost exactly a year later, the study was paused due to COVID-19. Dr Katrina Pollock who is the Chief Investigator and a Senior Clinical Research Fellow in Vaccinology at Imperial College London told us, “We have looked forward to this moment for months. The COVID-19 pandemic has caused a lot of uncertainty for many areas of research. Naturally, our team turned our full attention to delivering research to develop COVID-19 vaccines when it was most needed. Now, with COVID-19 vaccine roll-out underway, we have the opportunity to gradually restart other areas of vital research including the EAVI2020 studies”. To date, 54 volunteers have been enrolled into the study.

    At the University of Oxford, UK Prof Tomáš Hanke and the team will re-start in sequential order the T Cell Vaccine trials as of this month and as COVID-19 guidelines permit. Also, Dr Roger le Grand and Dr Nathalie Derreuddre-Bosquet with their team at Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), France, are expecting their NHP immunogenicity studies to commence in the summer.

    For further information on Europe’s COVId-19 response, the European Commission has placed up-to-date information on their website regarding COVID-19 response and action.

    Image by StockSnap from Pixabay.

  9. EAVI2020 Students in Focus: Dominik Damm (Department of Virology, Friedrich-Alexander-University (FAU), Erlangen, Germany)

    Leave a Comment

    Time to meet: Dominik Damm

    Where I started

    I wished to work in the field of HIV vaccine research since I was 13 years old. When I started my study of biology at the University of Regensburg, I tried to get into all immunology- and virology-related classes and seminars available and managed to do both my Bachelor and Master thesis on HIV-related topics. Finally, Prof. Klaus Überla gave me a PhD position in his group at the Department of Virology, which is part of the University Hospital in Erlangen, Germany. The group develops and tests nanoparticles as HIV vaccine candidates that present trimers of the HIV envelope protein (Env) on the surface and encapsulate heterologous T helper epitopes inside (T helper nanoparticles). We hope to recruit pre-existing T helper cells from childhood vaccinations in the vaccines that give intrastructural help to the Env-specific B cells, thereby modulating and improving the HIV humoral immune response. So, basically, I am currently doing what I always wanted to do and this gives me motivation every day I go to work.

    photo of Dominik Damm

    Dominik is in his 6th year of study and his research focusses on T helper nanoparticles as HIV vaccine candidates

    Luckily, the EAVI2020 program kicked off in the same year my PhD position started, so I got to experience this great consortium from the very beginning to now. Over the years I attended several PhD training courses and presented my research progress at the annual meetings.

    Where I am

    In principle, the training courses were reflections of the different EAVI2020 work packages with each course laying the focus on another aspect of the wide range of HIV vaccine research. Thus, we covered everything from antigen design, B and T cell vaccines as well as therapeutic approaches to animal models and ethical guidelines, industrial large-scale GMP production, etc. The courses were accompanied by workshops about grant writing and good scientific writing, which now helps me a lot during the final phase of my PhD.

    A wonderful fact of the EAVI2020 meetings was the ability to discuss hurdles, problems and prospects of your own research with other PhD students or leading HIV researchers without the bitter taste of rivalry, because everyone acts in concert and there is huge respect towards each other’s work. Also, the PIs always seemed to set great store on encountering PhD students at eye level in discussions or during presentations, which improved their self-esteem as young researchers.

    Since I did not have the chance to travel a lot as a child or teenager, it was refreshing to be among so many people from different countries and to actually visit these countries for the first time for meetings and training courses. Thus, the EAVI2020 program also enriched my cultural knowledge in many ways. My personal favourite was a one-week visit in Marit van Gils’ and Rogier Sanders’ labs (Academic Medical Center (AMC), The Netherlands) as part of the EAVI2020 student exchange program. Being there, I learned new lab techniques, had plenty of discussions with all the lab members that helped to modify my own project, and I could watch the famous SOSIP trimer production site.

    Where I am going

    As a student, I was always admiring the big international or US-based HIV vaccine consortia such as IAVI or CHAVD, where many scientists are working synergistically together, thereby producing and publishing high-impact research progress very efficiently and in a short amount of time. Now having the exact same thing among European and Australian HIV research groups is a fantastic opportunity and highly promotes competitive, creative strategies to end the HIV pandemic. I dearly hope that the EU will continue with similar or follow-up programs beyond Horizon2020.

    Currently, I perform some last experiments for my PhD project and write the resulting publications. After my PhD, I will try to receive a grant or fellowship for a Postdoc position and hopefully be able to kick off some kind of junior research group.

    Outside the lab

    Outside the lab, I like to clear my mind by going for a walk, while listening to music and catching some Pokémon. I also love to play the guitar and go to concerts, but mainly I spend quality time with my two little children.

  10. EAVI2020 receives 6-month project extension

    Leave a Comment

    Funding body, European Commission recognises blight of COVID-19 on Horizon2020 clinical research

    COVID-19 has had a considerable impact on the progress of EAVI2020’s clinical trial and lab work. Like many Horizon2020 projects involved in clinical trials, it was required to halt all lab work as a result of the pandemic and the European Commission (EC) have recognised this. It is anticipated that EAVI2020 clinical work can resume in the coming months, and the EAVI2020 consortium will use this compensatory time to continue the lab work when it is safe to return. The Consortium are very appreciated for this no-cost extension and they are positive that this will maximise the expected impacts of the EAVI2020 project.

    EAVI2020 will thus have an expected project closure date in April 2021.

    For further information, the European Commission has placed up-to-date information on their website regarding COVID-19 response and action.